Owner Glaxo Group Limited

Inventors Steward, Michael; Hamblin, Paul Andrew; Jespers, Laurent; Orecchia, Martin Anibal; Hussain, Farhana; Ellis, Jonathan Henry; Shah, Radha; Burden, Michael Neil; Batuwangala, Thil; Ashman, Claire; Lewis, Alan; Clegg, Stephanie Jane; De Wildt, Rudolf Maria

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2008328726

PCT Pub. Number WO2009/068649

Priority 60/991,449 30.11.07 US; 61/081,191 16.07.08 US; 61/027,858 12.02.08 US; 61/046,572 21.04.08 US; 61/084,431 29.07.08 US

Filing date 28 November 2008

Wipo publication date 4 June 2009

C07K 16/46 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 35/00 (2006.01) Antineoplastic agents

C07K 16/22 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/32 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins